Phase I trial of cisplatin, pemetrexed, and imatinib mesylate in chemo-naïve patients with unresectable malignant pleural mesothelioma

BACKGROUND: We conducted a phase I trial of cisplatin-pemetrexed-imatinib mesylate, an oral PDGFR inhibitor, in chemo-naive MPM patients. METHODS: A standard 3+3 dose-escalating trial was used with the endpoints of MTD, response rate, survival, safety/toxicity and tumor PDGFR levels. RESULTS: 17 MPM...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Clin Lung Cancer
Hoofdauteurs: Tsao, AS, Harun, N, Lee, J.J, Heymach, J, Pisters, K, Hong, WK, Fujimoto, J, Wistuba, I
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: 2013
Onderwerpen:
Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5080907/
https://ncbi.nlm.nih.gov/pubmed/24492162
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.cllc.2013.12.008
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items